Get the latest analysis on Hims & Hers Health, Inc. stock with valuation insights, business risks, and forecasts. Click here ...
Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs.
The U.S. Food and Drug Administration issued warning letters to Eli Lilly , Novo Nordisk and telehealth firm Hims & Hers ...
FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and ...
Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk ...
Online pharmacies are using a loophole to continue selling cheap weight loss drugs that are modeled on Ozempic and Mounjaro, ...
NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities ...
Few people consult a doctor before attempting weight loss. Hims offers virtual weight loss support for men, including consultations and prescriptions. Hims provides GLP-1 injections, meal replacements ...
Telehealth and wellness platform Hims & Hers Health (HIMS) recently disappointed investors with its mixed second-quarter results. While the company’s Q2 revenue grew 73% to about $545 million, it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback